Gold prices steady with focus on Ukraine-Russia, Jackson Hole
BANGKOK - NewGenIvf Group Limited (NASDAQ:NIVF), currently trading at $0.45 with a market capitalization of $2.25 million, has acquired cytometry technology and assets including 18 fully-constructed cell-sorting systems, eight partially constructed units, and six patents related to advanced microfluidic systems, the company announced Tuesday.
The acquisition builds upon NewGen’s earlier purchase of MicroSort technology, now rebranded as NewGenSort, which enables separation of X and Y chromosome-bearing sperm cells prior to in vitro fertilization procedures.
The company plans to deploy the 18 newly acquired cytometers initially in the United States, where the total number of IVF cycles performed at reporting SART member clinics increased from 389,993 in 2022 to 432,641 in 2023, according to the Society for Assisted Reproductive Technology.
With each sorting system capable of performing approximately four sorts per day, NewGen projects the ability to process more than 25,000 sorts annually, representing less than 6% of total U.S. IVF cycles. The company anticipates that annual gross revenue from its U.S. operations could exceed $20 million once fully operational. This projection represents significant growth potential compared to the company’s current annual revenue of $5.43 million. According to InvestingPro analysis, the stock is currently trading below its Fair Value.
The technology can be applied for couples seeking to balance family compositions or prevent certain genetic diseases, specifically X-linked or X-limited disorders.
NewGen expects to roll out the technology in the first quarter of 2026. The company currently operates fertility clinics in Thailand, Cambodia, and Kyrgyzstan.
"This strategic acquisition represents a significant milestone in NewGen’s expansion strategy," said Siu Wing Fung Alfred, Founder, Chairman, and CEO of NewGen, in a press release statement.
The acquired manufacturing capabilities are expected to enable NewGen to produce additional cytometers and consumables to support broader market penetration.
In other recent news, NewGenIvf Group Limited has announced a strategic investment of $45 million in UAE real estate, primarily focusing on properties near the upcoming Wynn Al Marjan Island resort in Ras Al Khaimah. This initiative is part of the company’s diversification strategy beyond its core IVF business. Additionally, NewGenIvf Group has secured a significant plot of land in Ras Al Khaimah’s Beach District and is exploring the feasibility of issuing digital tokens tied to this property. In a related development, NewGenDigital, a subsidiary of NewGenIvf, has signed a memorandum of understanding with BNW Real Estate Development for a joint venture in the same district.
Furthermore, NewGenIvf Group’s board has approved a reverse stock split and increased the number of authorized shares to an unlimited amount. In the realm of digital assets, NewGenIvf has invested $30 million in Solana, financed through existing credit facilities. This investment marks a notable expansion of the company’s digital asset portfolio and aligns with its focus on the blockchain sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.